Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Completes Acquisition of Adva-27a Patents

MONTREAL--(Marketwire - November 27, 2012) - Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCQB: SBFM), is pleased to announce that it has just completed acquisition of the worldwide patents covering Adva-27a from Institut National des Sciences Appliquees, a government research lab in France. Adva-27a is Sunshine Biopharma’s lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). One of the patents acquired is a US patent issued only a few months ago on August 7, 2012 under US patent number 8,236,935. This together with patents previously issued in Europe as well as other patent applications currently pending elsewhere around the world broadly cover Sunshine Biopharma’s flagship oncology drug candidate, Adva-27a.

“Having direct ownership of the patents strengthens our intellectual property position and gives us the leverage and freedom to carry on with our anticancer research program and expand the medical applications of Adva-27a,” said Dr. Steve N. Slilaty, Sunshine Biopharma’s CEO.

About Sunshine Biopharma Inc.

Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which it has licensed on an exclusive basis for the US territory from Advanomics Corporation.

About Advanomics Corporation

Advanomics Corporation is a privately held Canadian company focused on the research and development of treatments for cancer and other human diseases. Advanomics is conducting research and development in the area of Carbon-Difluoride Chemistry to generate novel anticancer compounds and in the area of RNA Technology for deciphering genomic information and rapid identification of disease related molecular targets for therapeutic intervention.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.